Market Overview
The Elastography Imaging market size was valued at USD 2,282 million in 2024 and is anticipated to reach USD 3,950.1 million by 2032, at a CAGR of 7.1% during the forecast period.
| REPORT ATTRIBUTE |
DETAILS |
| Historical Period |
2020-2023 |
| Base Year |
2024 |
| Forecast Period |
2025-2032 |
| Elastography Imaging Market Size 2024 |
USD 2,282 million |
| Elastography Imaging Market, CAGR |
7.1% |
| Elastography Imaging Market, Size 2032 |
USD 3,950.1 million |
The elastography imaging market is led by key players such as GE Healthcare, Siemens Healthineers, Philips, Canon Medical Systems Corporation, FUJIFILM Corporation, Samsung Medison, Hitachi Ltd, Mindray Bio-Medical Electronics, Toshiba America Medical Systems, and Esaote SpA. These companies maintain a competitive edge through continuous innovation, AI-enabled imaging advancements, and strong global distribution networks. North America stands as the leading region, holding approximately 38% of the global market share in 2024, driven by advanced healthcare infrastructure, high adoption of non-invasive diagnostic tools, and favorable reimbursement policies. Europe and Asia Pacific follow, with growing investments and expanding clinical applications fueling demand.
Market Insights
- The elastography imaging market was valued at USD 2,282 million in 2024 and is projected to reach USD 3,950.1 million by 2032, growing at a CAGR of 7.1% during the forecast period.
- Increasing prevalence of chronic liver diseases and the growing demand for non-invasive diagnostic techniques are major drivers accelerating market growth.
- Expanding applications in oncology and cardiology, along with the integration of AI and portable ultrasound devices, are key trends shaping the market landscape.
- The market is dominated by companies like GE Healthcare, Siemens Healthineers, Philips, Canon Medical Systems, and FUJIFILM, though high equipment costs and lack of standardization remain significant restraints.
- North America leads with a 38% market share, followed by Europe at 27% and Asia Pacific at 20%; by modality, ultrasound elastography dominates with over 65% share, while hepatology leads applications with over 40% market share.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
Download Sample
Market Segmentation Analysis:
By Modality
n the elastography imaging market, the ultrasound segment holds the dominant share, accounting for over 65% of the market in 2024. This dominance is attributed to its non-invasive nature, cost-effectiveness, and wide availability in clinical settings. Ultrasound elastography is extensively used for real-time assessment of tissue stiffness, particularly in liver and breast imaging. Additionally, technological advancements in portable ultrasound systems and improved imaging software have further accelerated adoption. Magnetic resonance elastography, while more precise, remains limited to specialized centers due to its higher cost and longer scan times.
- For instance, Philips Healthcare reported that its EPIQ Elite ultrasound platform, equipped with elastography capabilities, had been deployed in over 5,000 healthcare institutions globally as of 2023, with significant clinical uptake for liver assessments in both outpatient and hospital settings.
By Application:
Hepatology emerged as the leading application segment, capturing more than 40% of the market share in 2024. The growing global burden of chronic liver diseases such as hepatitis and cirrhosis has driven demand for non-invasive diagnostic tools like elastography. Clinicians increasingly rely on liver stiffness measurement to monitor fibrosis progression, reducing the need for biopsies. Moreover, the rising prevalence of non-alcoholic fatty liver disease (NAFLD) in developed and emerging economies contributes significantly to this segment’s growth. Other applications such as general imaging, cardiology, and breast imaging are gaining traction with expanding clinical validation.
- For instance, Echosens’ FibroScan®, a dedicated liver elastography system, had performed over 70 million examinations worldwide by mid-2023, underscoring its role in routine liver fibrosis assessment and management across hepatology clinics globally.
By End Use:
Hospitals dominate the end-use segment, holding a market share of over 60% in 2024, driven by higher patient volume, access to advanced imaging systems, and comprehensive diagnostic services. Hospitals are well-equipped with integrated imaging suites, enabling broader deployment of elastography techniques, especially for liver and oncology assessments. Additionally, favorable reimbursement frameworks in developed regions encourage adoption in hospital settings. Imaging centers, while growing steadily, primarily serve outpatient diagnostics and depend on referrals from physicians, limiting their market share compared to hospitals.
Market Overview
Rising Prevalence of Chronic Liver Diseases
he increasing global incidence of chronic liver diseases, including hepatitis B and C, cirrhosis, and non-alcoholic fatty liver disease (NAFLD), significantly drives the elastography imaging market. Elastography offers a non-invasive, reliable alternative to liver biopsy for assessing liver fibrosis and stiffness, making it an essential tool in hepatology. With liver-related diseases affecting millions globally, healthcare systems are prioritizing early diagnosis and monitoring, thereby fueling the adoption of elastography across hospitals and diagnostic centers.
- For instance, Siemens Healthineers announced in 2023 that more than 3,200 units of its ACUSON Sequoia ultrasound systems, which feature shear wave elastography, had been installed globally for liver diagnostics.
Advancements in Imaging Technology
Ongoing advancements in imaging technologies, particularly in ultrasound and magnetic resonance elastography, are propelling market growth. Innovations such as portable ultrasound devices, automated quantification, and real-time tissue elasticity measurement enhance diagnostic accuracy and patient outcomes. These improvements expand clinical applications and promote faster, more efficient imaging workflows. Additionally, the integration of AI-based image analysis tools and better software interfaces are improving diagnostic interpretation, leading to broader adoption across various medical specialties.
- For instance, GE HealthCare launched its LOGIQ E10 system, which includes AI-powered elastography features, and had shipped over 6,000 units globally by the end of 2023, contributing to increased diagnostic throughput and reduced variability in liver and breast imaging.
Growing Demand for Non-Invasive Diagnostic Solutions
There is a growing shift toward non-invasive diagnostic procedures due to patient preference, lower risks, and reduced healthcare costs. Elastography aligns with this trend by enabling the evaluation of tissue stiffness without the need for biopsies or contrast agents. This driver is particularly relevant in settings where repeat monitoring is required, such as in oncology or liver disease follow-up. The non-invasive nature of elastography enhances patient compliance and enables broader screening applications, especially in outpatient and resource-limited environments.
Key Trends & Opportunities
Expanding Applications in Oncology and Cardiology
While traditionally associated with hepatology, elastography imaging is increasingly being adopted in oncology and cardiology. In oncology, it assists in characterizing tumors in the breast, prostate, and thyroid by differentiating benign from malignant tissues. In cardiology, elastography is emerging as a tool for evaluating myocardial stiffness, aiding early detection of cardiac fibrosis. These expanding applications present significant growth opportunities, especially as clinical research validates the utility of elastography across more specialties.
- For instance, Hitachi’s Arietta 850 ultrasound platform, equipped with Real-time Tissue Elastography (RTE), has been used in over 250 peer-reviewed oncology studies globally, showcasing its value in tumor characterization and breast lesion differentiation.
Rising Adoption in Emerging Markets
Emerging economies in Asia-Pacific and Latin America are witnessing rising demand for advanced diagnostic tools, driven by increasing healthcare infrastructure, awareness, and patient volume. As healthcare systems modernize and prioritize early disease detection, elastography imaging is gaining momentum. Lower-cost ultrasound-based elastography systems are particularly attractive for these regions, providing an accessible and effective solution for chronic disease management. This creates strong growth potential for manufacturers willing to invest in regional partnerships and training.
- For instance, Mindray, a China-based medical technology company, reported in 2023 that it had deployed its Resona 7 elastography-enabled ultrasound systems in over 1,800 hospitals across Southeast Asia and Latin America, primarily in liver disease screening programs.
Key Challenges
High Equipment Costs and Limited Reimbursement
Despite its clinical benefits, elastography imaging systems, particularly magnetic resonance-based models, involve high capital investment and operational costs. This financial burden limits adoption, especially among smaller healthcare providers and facilities in cost-sensitive regions. Additionally, limited or inconsistent reimbursement policies in several countries restrict patient access and deter providers from offering elastography as a routine diagnostic tool, thereby hindering market expansion.
Lack of Skilled Operators and Standardization
The effectiveness of elastography imaging relies heavily on the operator’s skill and experience. Variability in results due to inconsistent technique and interpretation poses a significant challenge. Moreover, the absence of universally accepted standards for measurement and reporting reduces clinical confidence and hinders broader adoption. Training programs and standardized protocols are essential to ensure consistent, accurate outcomes across different clinical environments.
Limited Awareness Among Physicians and Patients
Awareness about elastography imaging’s diagnostic capabilities remains limited among general practitioners and patients, particularly outside hepatology. Many healthcare professionals continue to rely on conventional imaging or invasive methods like biopsies due to unfamiliarity with elastography’s benefits. This lack of awareness slows down adoption and restricts the technology’s penetration into new clinical segments, underutilizing its full potential.
Regional Analysis
North America
North America holds the largest share in the elastography imaging market, accounting for approximately 38% of the global revenue in 2024. This dominance is driven by the high prevalence of chronic liver and breast diseases, advanced healthcare infrastructure, and strong reimbursement frameworks. The presence of leading medical imaging companies and widespread adoption of technologically advanced systems support continued growth. The United States remains the key contributor, with increasing demand for non-invasive diagnostics and a focus on early disease detection. Ongoing investments in research and development also reinforce North America’s leadership in this space.
Europe
Europe represents the second-largest market, with a share of around 27% in 2024. Countries such as Germany, France, and the United Kingdom are at the forefront due to their strong public healthcare systems, early adoption of innovative technologies, and increasing awareness of non-invasive imaging modalities. Rising cases of liver fibrosis and cancer, coupled with favorable reimbursement policies, support the demand for elastography imaging. Furthermore, collaborations between academic institutions and imaging technology developers are accelerating clinical research and broadening the modality’s application across various medical disciplines.
Asia Pacific
Asia Pacific is emerging as the fastest-growing region in the elastography imaging market, holding a 20% share in 2024. Growth is primarily driven by rising healthcare investments, increasing awareness of early diagnosis, and the escalating burden of chronic liver diseases in countries such as China, India, and Japan. Government initiatives to modernize healthcare infrastructure and expand access to diagnostic services are enhancing market penetration. Additionally, the affordability and portability of ultrasound-based elastography systems make them suitable for high-volume clinical settings in both urban and rural areas across the region.
Latin America
Latin America holds a modest share of around 8% in the global elastography imaging market. The region is gradually adopting non-invasive diagnostic tools, driven by a rising incidence of liver and breast conditions and the need to reduce dependence on biopsy procedures. Brazil and Mexico are the primary contributors, benefiting from healthcare modernization and increasing public-private partnerships. However, limited reimbursement coverage and high equipment costs pose barriers to wider adoption. Nevertheless, the growing presence of international imaging system manufacturers and improved training initiatives indicate positive growth prospects.
Middle East & Africa
The Middle East & Africa region accounts for approximately 7% of the elastography imaging market in 2024. Market growth is supported by increasing investments in healthcare infrastructure, especially in Gulf countries like the UAE and Saudi Arabia. The rising burden of non-communicable diseases and expanding diagnostic capabilities in private hospitals are contributing to regional demand. However, factors such as limited access to advanced equipment in rural areas and a shortage of trained professionals continue to restrict market expansion. Nonetheless, ongoing health reforms and government-led initiatives are expected to gradually improve market penetration.
Market Segmentations:
By Modality
- Magnetic Resonance
- Ultrasound
By Application
- General Imaging
- Hepatology
- Cardiology
- Breast
By End Use
- Hospitals
- Imaging Centers
By Geography
- North America
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Competitive Landscape
The competitive landscape of the elastography imaging market is characterized by the presence of several global and regional players striving for technological advancement and market expansion. Leading companies such as GE Healthcare, Siemens Healthineers, Philips, Canon Medical Systems, and FUJIFILM Corporation dominate the market through continuous innovation, strong distribution networks, and strategic collaborations. These players focus on enhancing ultrasound and magnetic resonance elastography technologies with features like AI integration, real-time imaging, and improved user interfaces. Emerging companies, particularly in Asia, are gaining traction by offering cost-effective and portable solutions. Additionally, partnerships with hospitals and research institutions for clinical validation and training support competitive differentiation. Market players are also investing in expanding their geographic reach, especially in high-growth regions like Asia Pacific and Latin America. As demand for non-invasive diagnostic tools continues to rise, competition is expected to intensify, driving further innovation, product launches, and pricing strategies aimed at strengthening market position.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
Key Player Analysis
- Siemens
- Mindray Bio-Medical Electronics Co., Ltd.
- Hitachi, Ltd
- Samsung Medison Co., Ltd.
- Toshiba America Medical Systems, Inc.
- FUJIFILM Corporation
- Esaote SpA
- GE Healthcare
- Koninklijke Philips N.V.
- Canon Medical Systems Corporation
Recent Developments
- In February 2025, Philips unveiled AI-enabled Elevate suite at ECR 2025 with automated elastography workflows that trim exam durations by 60%.
- In November 2023, ZEISS introduced Lattice structured-illumination microscopy that surpasses optical resolution limits, complementing elastography in tissue characterization.
- In November 2023, ZEISS introduces new Lattice structured illumination microscopy (SIM) to overcome the physical resolution limits of light microscopy.
- In July 2023, at the Microscopy and Microanalysis (M&M) 2023 Conference, ZEISS Microscopy introduces its latest product launch and highlights new researchers through interactive display features.
- In June 2023, Nikon Instruments Inc. has revealed the development and release of “ECLIPSE Ui,” a comprehensive microscope-based viewing system crafted for seamless clinical observations, catering to both in-person and remote pathological assessments.
Market Concentration & Characteristics
The Elastography Imaging Market exhibits a moderately concentrated structure, with a few dominant players such as GE Healthcare, Siemens Healthineers, Philips, Canon Medical Systems, and FUJIFILM Corporation holding a significant share. These companies drive innovation through advanced imaging technologies, AI integration, and product development focused on non-invasive diagnostics. It reflects a high degree of technological advancement and product differentiation, especially in ultrasound-based systems, which lead the market in both usage and revenue. Entry barriers remain relatively high due to capital intensity, regulatory compliance, and the need for clinical validation. Pricing remains competitive, with established players leveraging scale and distribution networks to maintain market leadership. Smaller firms and new entrants focus on cost-effective and portable solutions to gain regional presence, particularly in Asia Pacific and Latin America. Customer preference for real-time, accurate, and non-invasive imaging methods shapes product design and commercialization strategies. The market also depends on skilled operators and reimbursement frameworks, influencing adoption rates across regions.
Report Coverage
The research report offers an in-depth analysis based on Modality, Application, End Use and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
- The market will continue to grow steadily driven by the rising demand for non-invasive diagnostic technologies.
- Advancements in ultrasound and magnetic resonance elastography will enhance diagnostic accuracy and expand clinical applications.
- Increasing prevalence of liver diseases and cancer will sustain demand across hospitals and imaging centers.
- Integration of artificial intelligence will improve image interpretation and workflow efficiency in clinical settings.
- Portable and cost-effective devices will gain traction in outpatient clinics and emerging markets.
- Training programs and standardized imaging protocols will address skill gaps and improve consistency in results.
- Growing adoption in oncology, cardiology, and musculoskeletal diagnostics will diversify revenue streams.
- Expansion into rural and underserved healthcare areas will create new opportunities for manufacturers.
- Strategic partnerships among healthcare providers, device manufacturers, and research institutions will drive innovation.
- Regulatory support and reimbursement improvements will positively influence market accessibility and adoption.
